Recently, GlaxoSmithKline was handed the largest fine ever imposed by the PRC (£300 million) after it was found guilty of bribery. Five of its employees were also given suspended prison sentences.
In this article, Squire Patton Boggs lawyers Dan Roules and Louise Roberts look at the impact that the verdicts may have on multinational companies operating in China, and whether the proceedings in China may not be the end of the matter.
*This article was originally published by LexisNexis and is reproduced with permission.
